In this study, we evaluated multi-omic features of paired primary and recurrent tumors from 27 BRCA1/2 mutation carriers, representing 13 breast cancers (primarily TNBC) and 14 ovarian cancers (mostly high-grade serous). This evidence concerns the gene BRCA1 and ovarian carcinoma.